Back

Understanding Comorbidities in Hypermobile Ehlers-Danlos Syndrome: Could a Viral Infection Lead to a Diagnosis?

Pearson, M. L.; Laraway, B. J.; Elias, E. R.; Bilousova, G.; Haendel, M. A.; National Clinical Cohort Collaborative (N3C) Consortium,

2025-10-24 health informatics
10.1101/2025.10.22.25338573 medRxiv
Show abstract

Hypermobile Ehlers-Danlos Syndrome (hEDS) is a complex, underdiagnosed connective tissue disorder characterized by widespread symptoms affecting multiple organ systems. Recent clinical observations suggest that individuals with hEDS may be at increased risk for persistent symptoms following COVID-19, commonly referred to as Long COVID. Using data from over 19 million patients across the United States, we examined associations between hEDS, COVID-19 infection, Long COVID, and related chronic conditions. We identified just over 25,000 individuals with hEDS and estimated a prevalence of approximately 1 in 800, which is higher than previously recognized. While rates of COVID-19 infection were similar between patients with hEDS and matched controls, patients with hEDS were significantly more likely to develop Long COVID. This risk was especially elevated among patients with hEDS with overlapping conditions commonly seen in post-viral syndromes, including autonomic dysfunction, immune dysregulation, and chronic fatigue. Specifically, individuals with postural orthostatic tachycardia, mast cell-related symptoms, or chronic fatigue syndrome had the highest rates of Long COVID. Temporal diagnostic analyses revealed that many patients received an hEDS diagnosis only after a COVID-19 infection, suggesting that viral illness may exacerbate or reveal previously unrecognized symptoms. Patients with hEDS also exhibited higher odds of having additional risk factors for severe or prolonged illness, including chronic lung and autoimmune conditions, depression, and cerebrovascular disease. These findings highlight a previously unrecognized vulnerability in patients with hEDS and underscore the need for greater clinical awareness of their heightened risk for persistent post-COVID illness. Improved screening, earlier diagnosis, and integrated care pathways are urgently needed to support this complex and underserved patient population. Author summaryWe studied patients with hypermobile Ehlers-Danlos Syndrome (hEDS), a connective tissue condition that affects joints, skin, and many body systems. This condition is often misunderstood or overlooked, leaving many people undiagnosed. During the COVID-19 pandemic, people with hEDS appeared to experience more long-term symptoms after infection, a condition often called Long COVID. Here, we analyzed the health records of millions of patients in the United States to better understand post-viral outcomes. Patients with hEDS were more likely to be diagnosed with Long COVID compared to similar patients without hEDS. This was especially true for those who also had conditions such as chronic fatigue, immune conditions, or issues with heart rate and blood pressure regulation. In many cases, people were diagnosed with hEDS for the first time only after they had COVID-19, suggesting the virus may worsen or reveal symptoms that had been previously missed. Our findings show that hEDS may be more common than previously thought and that such patients face higher risks after COVID-19. Greater awareness and earlier recognition of hEDS could improve care for many patients with complex, long-lasting symptoms

Matching journals

The top 16 journals account for 50% of the predicted probability mass.

1
Journal of Personalized Medicine
28 papers in training set
Top 0.1%
7.0%
2
Orphanet Journal of Rare Diseases
18 papers in training set
Top 0.1%
7.0%
3
Journal of the American College of Cardiology
12 papers in training set
Top 0.1%
6.5%
4
American Journal of Medical Genetics Part A
17 papers in training set
Top 0.1%
3.7%
5
Science Translational Medicine
111 papers in training set
Top 0.7%
3.7%
6
Cell Reports Medicine
140 papers in training set
Top 1%
3.7%
7
Frontiers in Neurology
91 papers in training set
Top 2%
2.7%
8
Scientific Reports
3102 papers in training set
Top 49%
2.1%
9
Annals of the Rheumatic Diseases
32 papers in training set
Top 0.3%
2.1%
10
Nature Communications
4913 papers in training set
Top 46%
2.1%
11
GENETICS
189 papers in training set
Top 0.5%
1.9%
12
PLOS ONE
4510 papers in training set
Top 49%
1.9%
13
JCI Insight
241 papers in training set
Top 3%
1.7%
14
Human Genetics and Genomics Advances
70 papers in training set
Top 0.3%
1.7%
15
Journal of Medical Virology
137 papers in training set
Top 2%
1.7%
16
PLOS Genetics
756 papers in training set
Top 8%
1.7%
50% of probability mass above
17
Disease Models & Mechanisms
119 papers in training set
Top 1%
1.5%
18
eBioMedicine
130 papers in training set
Top 2%
1.4%
19
JAMA Pediatrics
10 papers in training set
Top 0.1%
1.4%
20
Arthritis & Rheumatology
33 papers in training set
Top 0.4%
1.3%
21
Frontiers in Public Health
140 papers in training set
Top 6%
1.1%
22
Annals of Neurology
57 papers in training set
Top 2%
1.0%
23
eClinicalMedicine
55 papers in training set
Top 1%
1.0%
24
Acta Neuropsychiatrica
12 papers in training set
Top 0.7%
1.0%
25
The American Journal of Human Genetics
206 papers in training set
Top 3%
0.9%
26
Human Molecular Genetics
130 papers in training set
Top 3%
0.9%
27
npj Digital Medicine
97 papers in training set
Top 3%
0.8%
28
Annals of Internal Medicine
27 papers in training set
Top 0.8%
0.8%
29
BMJ Open
554 papers in training set
Top 12%
0.8%
30
Critical Care
14 papers in training set
Top 0.5%
0.8%